Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs SPDR Kensho Final Frontiers ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while SPDR Kensho Final Frontiers ETF trades at $100.25 (market cap $165.02M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 5.9× SPDR Kensho Final Frontiers ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SPDR Kensho Final Frontiers ETF for 14 Days on average.
| MRVI | ROKT | |
|---|---|---|
Market Cap | $977.37M | $165.02M |
Volume | 2,742,564 | 15,155 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $136.68 |
52-Week Low | $2.83 | $72.93 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
ROKT (SPDR S&P Kensho Final Frontiers ETF) trades at $101.88, down 1.0% today, with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The ETF provides diversified exposure to aerospace and defense companies, though key financial ratios are currently unavailable. Recent news highlights growing investor interest in space-related investments through diversified vehicles like ROKT rather than individual space stocks.
The ETF offers efficient exposure to the final frontiers theme but faces challenges from high operational costs and profitability timelines in the space sector. Current bearish technical indicators suggest near-term pressure, while long-term growth potential in aerospace and defense remains supported by industry developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
